Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03777410 · ClinicalTrials.gov registry record
Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma
A clinical trial, sponsored by Travera.
- Terminated
- Registry status
- 33
- Enrollment target
NCT03777410: Clinical Trial study, sponsored by Travera.
NCT03777410 is a clinical trial that was terminated before completion, run by Travera. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03777410 was terminated before completion, sponsored by Travera.
- TERMINATED
- Registry status
- 33 participants
- Enrollment target
Study Summary
This study will collect bone marrow (BM) aspirate samples from patients with relapsed refractory multiple myeloma (RRMM) prior to the start of a new treatment regimen for the purposes of prospectively measuring single-cell mass accumulation rate (MAR) as a biomarker of patient response to that regimen. The primary study objective is to explore whether the single-cell MAR biomarker can predict patient response in RRMM patients. In order to enable this primary objective, two patient cohorts will be required. First, a small vanguard cohort of patients with treatment naïve disease to define drug concentrations used for testing, and second, the main RRMM patient cohort. Data will be collected to estimate the biomarker's predictive properties (accuracy, sensitivity, specificity), and to support improvement of the MAR biomarker through additional research and discovery within the study dataset.
Primary Outcome
The best International Myeloma Working Group (IMWG) response of each patient over 4 months of therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2019-02-11 |
| Est. Completion | 2024-06-30 |
Why NCT03777410 stopped before completion
NCT03777410 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 33 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03777410 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03777410 about?
NCT03777410 is a clinical study titled "Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma". This study will collect bone marrow (BM) aspirate samples from patients with relapsed refractory multiple myeloma (RRMM) prior to the start of a new treatment regimen for the purposes of prospectively measuring single-cell mass accumulation rate (MAR) as a biomarker of patient response to that regim...
What is the current status of trial NCT03777410?
This trial is currently terminated. The enrollment target is 33 participants. The study started on 2019-02-11. Estimated completion is 2024-06-30.
Who is sponsoring clinical trial NCT03777410?
This trial is sponsored by Travera, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI